November 18, 2014Open Access
View Full PaperAtenolol versus Losartan in Children and Young Adults with Marfan's Syndrome
Structured PICO
Does losartan reduce the rate of aortic-root dilatation compared to atenolol in children and young adults with Marfan's syndrome?
P
Population
Children and young adults with Marfan's syndrome
I
Intervention
Losartan
C
Comparator
Atenolol
O
Outcome
Rate of aortic-root dilatationsurrogate
In children and young adults with Marfan's syndrome, losartan did not significantly reduce the rate of aortic-root dilatation compared to atenolol over 3 years.
Abstract
Among children and young adults with Marfan's syndrome who were randomly assigned to losartan or atenolol, we found no significant difference in the rate of aortic-root dilatation between the two treatment groups over a 3-year period. (Funded by the National Heart, Lung, and Blood Institute and others; ClinicalTrials.gov number, NCT00429364.).